Expression correlation between Efp and Plk3 in estrogen receptor-positive breast cancer

您当前的位置：

首页 >

文章列表页 >

Expression correlation between Efp and Plk3 in estrogen receptor-positive breast cancer

更新时间：2025-12-31

- Expression correlation between Efp and Plk3 in estrogen receptor-positive breast cancer
- China Oncology Vol. 26, Issue 10, Pages: 848-853(2016)
- 作者机构：
  
  云南省肿瘤医院/ 昆明医科大学第三附属医院乳腺外一科,云南,昆明,650118
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2016.10.007
  CLC：
- Published Online：17 November 2016，
  
  Published：17 November 2016
- 稿件说明：
移动端阅览
段佳君,邹天宁,张　季,等. ER阳性乳腺癌中Efp和Plk3蛋白表达相关性探讨[J]. 中国癌症杂志, 2016, 26(10): 848-853.

段佳君, 邹天宁, 张　季. Expression correlation between Efp and Plk3 in estrogen receptor-positive breast cancer[J]. China Oncology, 2016, 26(10): 848-853.
段佳君,邹天宁,张　季,等. ER阳性乳腺癌中Efp和Plk3蛋白表达相关性探讨[J]. 中国癌症杂志, 2016, 26(10): 848-853. DOI： 10.19401/j.cnki.1007-3639.2016.10.007.

段佳君, 邹天宁, 张　季. Expression correlation between Efp and Plk3 in estrogen receptor-positive breast cancer[J]. China Oncology, 2016, 26(10): 848-853. DOI： 10.19401/j.cnki.1007-3639.2016.10.007.

摘要

背景与目的：长期以来，雌激素受体(estrogen receptor，ER)阳性乳腺癌患者对内分泌治疗耐药是临床上棘手的难题。目前研究表明，雌激素效应环指蛋白(estrogen-responsive finger protein，Efp)和polo样激酶3(polo-like kinase 3，Plk3)的表达与乳腺癌发展具有密切关系。该研究旨在探讨ER阳性乳腺癌中Efp和Plk3蛋白表达相关性，了解Efp和Plk3表达变化在耐药中的作用。方法：应用免疫组织化学SP法检测74例ER阳性乳腺癌组织中Efp和Plk3蛋白表达情况，结合临床资料进行分析。并采用实时荧光定量聚合酶链反应(real-time fluorescent quantitative polymerase chain reaction，RTFQ-PCR)及蛋白[质

]

印迹法(Western blot)检测ER阳性乳腺癌MCF-7细胞中Efp和Plk3的基因和蛋白表达变化。结果：74例ER阳性乳腺癌组织中Efp和Plk3蛋白表达与患者的临床病理特征未见任何关系(P0.05)，其中有51例(68.9%)患者Efp表达阳性和23例(31.1%)患者Plk3表达阳性，χ

2

检验分析结果显示，ER阳性乳腺癌组织中Efp和Plk3具有显著的负相关关系(χ

2

=8.837，P0.05)。RTFQ-PCR检测结果显示，MCF-7细胞经雌激素刺激后Efp mRNA的表达显著增加，而Plk3 mRNA的表达无明显变化。Western blot检测结果显示，MCF-7细胞经雌激素和MG132刺激后，Efp的蛋白表达较MG132组显著增加，而Plk3蛋白表达明显下降。结论：在ER阳性乳腺癌患者中Efp和Plk3的蛋白表达呈负相关，Efp高表达可促进Plk3的蛋白降解，对内分泌耐药过程的形成可能产生一定影响。

Abstract

Background and purpose: Estrogen receptor (ER)-positive breast cancer always presents a dilemma for resistance to endocrine therapy in a long time. The recent studies showed that the expression of estrogenresponsive finger protein (Efp) and polo-like kinase 3 (Plk3) had a close relationship with breast cancer development. This study was to explore the expression correlation between Efp and Plk3 in ER-positive brea

st cancer in order to understand the influence of Efp and Plk3 on the drug resistance. Methods: The expression of Efp and Plk3 in 74 cases of ER-positive breast cancer was detected by SP immunohistochemistry. The clinical significance was then analyzed. Real-time fluorescent quantitative polymerase chain reaction (RTFQ-PCR) and Western blot were used to detect the expression of Efp and Plk3 in ER-positive MCF-7 cells. Results: No significant relationship was found between Efp and Plk3 expression and the clinicopathological features of 74 cases of ER-positive breast cancer (P0.05). The number of cases whose Efp showed positive expression was 51 (68.9%)

while the number of cases whose Plk3 showed positive expression was 23 (31.1%). Chi-square test analysis showed the expression of Efp and Plk3 was negatively correlated in 74 cases of ER-positive breast cancer (χ

2

=8.837

P0.05). The result of RTFQ-PCR showed that the expression of Efp mRNA in MCF-7 cells was up-regulated by estrogen stimulation

whereas Plk3 mRNA was not changed. The result of Western blot showed that the expression of Efp protein in MCF-7 cells was increased by estrogen and MG132 stimulation

whereas Plk3 protein was decreased. Conclusion: The expression of the Efp protein is negatively correlated with Plk3 protein in ER-positive breast cancer. High expression of Efp may be involved in the resistance to endocrine therapy.

关键词

Keywords

references

0

Views

2086

下载量

0

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Related Articles

Research advances in estrogen receptor low positive early breast cancer

Mechanism of AMPK-enhanced chemosensitivity of breast cancer MCF-7/adr cells to adriamycin

Expressions of miRNA27a and miRNA451 in ovarian cancer and breast cancer cells and its correlation with drug resistance by targeting MDR1/P-glycoprotein

Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)

Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives

Related Author

Yizi JIN

Mingxi LIN

Cheng ZENG

Qing GUO

Jian ZHANG

崔文贤

许柯青

李元国

Related Institution

Department of Medical Oncology, Fudan University Shanghai Cancer Center; Phase Ⅰ Clinical Trial Center, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

常州市第七人民医院检验科

广州医学院附属广东省妇幼保健院妇科

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital& Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

AI问答

⁰